Using RWD to Build an ECA With Confidence

Published on

November 20, 2026

By

Flatiron Health

Regulatory pathways in oncology are evolving rapidly, but for emerging pharma and biotech, generating credible comparative evidence is only getting harder. External control arms (ECAs) built on real-world data sourced directly from EHR systems offer a path forward–providing the clinical depth, timeliness, and rigor needed to hold up under regulatory scrutiny where historical benchmarks and traditional data sources may fall short.

In this webinar, current and former FDA directors, Flatiron's Director of Research of Sciences, and real-world data strategy leads from Revolution Medicines and Regeneron discuss

  • Regulatory considerations when evaluating external control arms today, and what it takes to count as credible evidence in a submission
  • How ECAs can inform go/no-go decisions, refine trial design and strengthen single-arm results before you file
  • How RWD has been used in ECAs that contributed to a regulatory approval, and what sets them apart
The views and opinions expressed in this webinar are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.